Clinical Trials Directory

Trials / Sponsors / Arbutus Biopharma Corporation

Arbutus Biopharma Corporation

Industry · 11 registered clinical trials — 1 currently recruiting.

StatusTrialPhaseStarted
RecruitingLong-Term Follow-up Study for Subjects With CHB Previously Treated With Imdusiran (AB729)
Long Term Follow-up
—2024-07-11
WithdrawnStudy of Imdusiran (AB-729) in Combination With Intermittent Dosing of Durvalumab in Subjects With Chronic HBV
Hepatitis B, Chronic
Phase 22024-05-01
CompletedSafety, Tolerability, PK & PD of AB-101 Following Oral Administration in Healthy and CHB Subjects.
Chronic Hepatitis b
Phase 12023-08-30
CompletedOpen-Label Study of AB-729, Nucleos(t)Ide Analogue and Pegylated Interferon Alfa-2a in Subjects With Chronic H
Chronic Hepatitis b
Phase 22021-10-29
TerminatedSafety, Tolerability, and Pharmacokinetics of AB-836 in Healthy Subjects and Subjects With Chronic HBV Infecti
Chronic Hepatitis
Phase 12021-06-25
CompletedStudy of ARB-001467 in Subjects With Chronic HBV Infection Receiving Nucleos(t)Ide Analogue Therapy
Hepatitis B, Chronic
Phase 22015-12-01
CompletedSafety, Pharmacokinetics and Preliminary Anti-Tumor Activity of Intravenous TKM-080301 in Subjects With Advanc
Hepatocellular Carcinoma, Hepatoma, Liver Cancer, Adult
Phase 1 / Phase 22014-06-01
TerminatedSafety, Tolerability and Pharmacokinetic First in Human (FIH) Study for Intravenous (IV) TKM-100802
Ebola Virus Infection
Phase 12014-01-01
TerminatedSafety, Tolerability and Pharmacokinetic First in Human (FIH) Study of Intravenous (IV) TKM-100201 Infusion
Ebola Virus Infection
Phase 12012-01-01
CompletedA Dose Finding Study of TKM-080301 Infusion in Neuroendocrine Tumors (NET) and Adrenocortical Carcinoma (ACC)
Cancer, Neuroendocrine Tumors, NET
Phase 1 / Phase 22010-12-01
TerminatedStudy to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) of Liposomal siRN
Hypercholesterolemia
Phase 12009-06-01